Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 201 - 250 out of 103,247

Document Document Title
WO/2014/155184A1
A method for treating Parkinson's disease in a mammal in need thereof is disclosed. The method comprises administering to the mammal an effective amount of a compound of any one of Structural Formulas (I-III), or a pharmaceutically accep...  
WO/2014/157107A1
[Problem] To provide a polypeptide which has highly homogeneous sialylated sugar chains attached thereto and has an interferon β activity. [Solution] A sugar chain-containing polypeptide that is selected from the group consisting of (1)...  
WO/2014/155186A1
The invention relates to a food supplement comprising isomaltulose, whey protein concentrate, linseed, whey mineral complex, short-chain fructooligosaccharides, lactoferrin, and vitamin B6. This food supplement was developed to be used a...  
WO/2014/160502A1
This disclosure relates to uridine nucleoside derivatives, compositions comprising therapeutically effective amounts of those nucleoside derivatives and methods of using those nucleoside derivatives or compositions in treating disorders ...  
WO/2014/154897A1
The present invention relates to novel compounds of Formula (I) and their use in therapeutic treatments.  
WO/2014/159591A1
The present invention is directed to compounds of Formula I: wherein ring A is phenyl, naphihalenyl, pyridyl, quinolinyl, isoquinolinyl, imidazopyridyl, furanyi, tlisazolyl, isoxazolvl, pyrazolyl, imidazothiazolyi, benzimidazolyl, or ind...  
WO/2014/155351A1
A composition comprises as active ingredient an extract of a plant or plants from the Mesembryanthemaceae family, such as Mesembryanthemum tortuosum, having an alkaloid profile comprising at least 70% (w/w) stabilized mesembrine. The ext...  
WO/2014/160480A1
3beta, 17beta disubstituted steroidal compounds, pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, are provided for the prevention and treatment of a variety of CNS-related conditions.  
WO/2014/160138A3
The present invention generally relates to compositions and methods for topical or transdermal delivery, including treatment and prevention of learning and memory disorders, and enhancement of learning or memory. In some cases, the compo...  
WO/2014/147178A1
The present invention relates to Histone deacetylases 6 (HDAC6) inhibitors and compositions containing the same. Methods of treating diseases and conditions wherein inhibition of HDAC6 provides a benefit, like a cell proliferative diseas...  
WO/2014/151752A1
Provided herein are methods of treating a peripheral nerve injury in a subject. The methods include administering to the subject at or near the site of the peripheral nerve injury an effective amount of a composition comprising an agent ...  
WO/2014/148574A1
The purpose of the present invention is to find a substance capable of inhibiting the production of IL-2. The production of IL-2 can be inhibited with a compound represented by general formula (I) (wherein R1 to R4 and A are as defined i...  
WO/2014/150873A1
Sequestrants of AGE precursors comprise amines separated by 2, 3 or 4 carbons. Sequestrants of AGE precursors can be used as pharmaceutical agents and in pharmaceutical compositions. The sequestrants of AGE precursors are particularly us...  
WO/2014/147636A8
The present invention relates to novel quinoline compounds of formula (I), and their pharmaceutically acceptable salts and process for their preparation. The compounds of formula (I) are useful in the treatment of various disorders that ...  
WO/2014/148951A1
The invention relates to the field of medicine, and more particularly to psychopharmacology and psychoneurology. A combination of drugs comprising various active agents, which do not have a direct analgesic effect, in conjunction with on...  
WO/2014/147636A1
The present invention relates to novel quinoline compounds of formula (I), and their pharmaceutically acceptable salts and process for their preparation. The compounds of formula (I) are useful in the treatment of various disorders that ...  
WO/2014/152818A1
Described herein are methods of inhibiting or reversing the progression of cataract formation or presbyopia in an eye by administering a γ-crystallin charge masking agent. Both presbyopia and cataracts are caused by aggregation of the s...  
WO/2014/146747A1
Compounds of the formula (I), in which R, X1, X2, X3, X4, R1, R2 and q have the meanings indicated in Claim 1, are inhibitors of fatty acid synthase, and can be employed, inter alia, for the treatment of diseases such as cancer, cardiova...  
WO/2014/152537A1
The present invention is directed to a compound of Formula (I) Formula (I) The invention also relates to pharmaceutical compositions comprising compounds of Formula (I) and methods comprising administering to a subject at least one compo...  
WO/2014/148646A1
The present invention addresses the problems of: providing a method for producing motor neurons from pluripotent stem cells quickly and in synchronisation, said motor neurons being satisfactorily provided with the properties of inherent ...  
WO/2014/146699A1
The invention relates to antagonists of the cannabinoid receptor CBI for use in the treatment and prevention of diseases associated with neural dendritic abnormalities, such as Down's syndrome, Angelman's syndrome, Rett syndrome and tube...  
WO/2014/150344A1
In its many embodiments, the present invention provides certain C2-azaspirosubstituted iminothiazine dioxide compounds. The novel compounds of the invention are useful as BACE inhibitors and/or for the treatment and prevention of various...  
WO/2014/149266A3
Acellular compositions for treating inflammation, comprising two or more of IL1-ra, sTNF-R1, sTNF-RII, IGF-I, EGF, HGF, PDGF-AB, PDGF-BB, VEGF, TGF-β1, and sIL-1RII. Components of the acellular compositions may be derived from biologic ...  
WO/2014/146493A1
The instant invention provides compounds of formula I which are JAK inhibitors, and as such are useful for the treatment of JAK-mediated diseases such as rheumatoid arthritis, asthma, COPD and cancer.  
WO/2014/150981A1
The present invention provides compounds having a structure according to Formula I. The invention further provides pharmaceutical compositions including the compounds of the invention and methods of making and using the compounds and com...  
WO/2014/153226A1
Described herein are compounds of Formula (I), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Compounds described herein are useful for inhibiting arginine methyltransferase activity. Methods of using...  
WO/2014/152444A1
Proivded herein are compounds and methods for inhibiting histone deacetylase ("HDAC") enzymes (e.g., HDACl, HDAC2, and HDAC3).  
WO/2014/148455A1
Provided is a novel terpenoid derivative which exhibits anti-inflammatory action and cytoprotective action by activating Keap1/Nrf2/ARE signal transduction pathways. Terpenoid derivative A is represented by formula (1).  
WO/2014/151628A1
Methods are provided for treating Autism Spectrum Disorder (ASD) using helminthic parasite preparations.  
WO/2014/151742A1
Disclosed herein are stable pharmaceutical dosage forms containing carbidopa, levodopa, and entacapone. The dosage forms are prepared by mixing carbidopa, levodopa, and entacapone and forming granules. In some embodiments the granules al...  
WO/2014/151747A1
Novel antibodies, methods and compositions for treatment of a disease which is susceptible to amelioration by the blocking of APP cleavage.  
WO/2014/152725A1
Compounds of formula (I), and pharmaceutically acceptable salts thereof, can modulate the activity of one or more SIP receptors and/or the activity of autotaxin (ATX). Formula (1)  
WO/2014/151529A1
The present invention provides compounds, compositions, kits, and methods which are effective for mitigating, treating, or ameliorating a DNA repair-deficiency disorder or a symptom of a DNA repair-deficiency disorder. The compounds, com...  
WO/2014/151697A1
Provided herein are compositions, including intranasal compositions, which include geranylgeranyl acetone (GGA) and/or derivatives thereof and methods for treating a neural disease, disorder or condition with the same. Also provided here...  
WO/2014/151719A1
Provided herein are sublingual formulations of geranylgeranylacetone, geranylgeranylacetone derivatives, and drug conjugates of each thereof, and methods of using them. Also provided are methods for treating osteopenia with geranylgerany...  
WO/2014/146490A1
Compounds of formula I are provided, which are JAK inhibitors and are useful for the treatment of JAK-mediated diseases such as rheumatoid arthritis, asthma, COPD and cancer.  
WO/2014/151258A1
The present invention is directed to substituted pyridine derivatives, pharmaceutical compositions containing said derivatives and the use of said derivatives in the treatment of disorders mediated by c-fms kinase. The present invention ...  
WO/2014/150687A1
The present disclosure is directed to the administration of specific carbohydrate systems to a pregnant and/or lactating woman for improving one or more characteristics in offspring, for example cognition and/or bone health. The carbohyd...  
WO/2014/152621A1
The present invention is directed to a compound of Formula (I): wherein: The present invention is directed to a compound of Formula (I): wherein: • n is an integer from 0-1; • X is CH2 when n is 0, or X is CH2 or oxygen when n is 1; ...  
WO/2014/147353A1
The invention relates to the use of 4-{3-[cis-hexahydrocyclopenta[C]pyrrole-2(1H)-yl]propoxy}ben zamide of formula (I): or of the acid or base addition salts thereof, which is pharmaceutically acceptable for treating neuropathic pain as ...  
WO/2014/146553A1
The present invention belongs to the field of pharmaceutical chemistry, and, in particular, disclosed therein are a flavonoid derivative and use thereof. Disclosed is a flavonoid derivative having the structure of general formula (I) or ...  
WO/2014/153172A1
Described herein are compounds of Formula (I-a) and (I-b), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Compounds of the present invention are useful for inhibiting PRMT1 activity. Methods of using ...  
WO/2014/152144A1
Compounds of formula (I) and methods are provided for the treatment of disease or conditions in which modification of cholinergic, especially muscarinic receptor activity, has a beneficial effect.  
WO/2014/151387A1
Described are transdermal drug delivery compositions comprising amphetamine, methods of making transdermal drug delivery compositions comprising amphetamine, and therapeutic methods of using them. In specific embodiments, the composition...  
WO/2014/153529A1
The invention provides modulators of the nociceptin receptor (NOP), including both agonists and antagonists. A compound of the invention can be a selective modulator of NOP with respect to the μ- and κ- opioid receptors (MOP and KOP), ...  
WO/2014/152589A1
The present invention is directed to a compound of Formula (I) or (la) The invention also relates to pharmaceutical compositions comprising compounds of Formula (I) or (la) and methods comprising administering of compounds of Formula (I)...  
WO/2014/151338A1
The present invention provides methods for treating or limiting development of multiple sclerosis by administering angiotensin peptides to a subject with multiple sclerosis or at risk of developing multiple sclerosis.  
WO/2014/144512A1
A high dose rapidly dispersing three-dimensionally printed dosage form comprising a high dose of levetiracetam in a porous matrix that disperses in water within a period of less than about 10 seconds is disclosed. Also disclosed are meth...  
WO/2014/139443A1
Provided are a low immunogenicity human cell and a preparation method therefor. The cell is a modified human cell. Compared with a corresponding wild-type cell, the human leukocyte antigen (HLA) protein or polypeptide of surface of the c...  
WO/2014/144231A1
The invention relates to methods for treating stress sensitive condition. For instance a subject having or at risk of having a stress-sensitive condition may be treated with a growth hormone (GH) antagonist in an effective amount to trea...  

Matches 201 - 250 out of 103,247